Standalone Phase 2 weight trial
In a dose-finding Phase 2 trial, standalone cagrilintide, tested at several doses, produced significant reductions in body weight in adults with overweight/obesity versus placebo. Permanent treatment discontinuation occurred in 10% of participants overall, 4% due to adverse events.
- Study type
- Human trial
- Population
- Adults aged 18 or above without diabetes, BMI 30 or above (or 27 or above with hypertension or dyslipidaemia), randomised across multiple cagrilintide dose groups (approximately 100 to 102 per group), a liraglutide active comparator arm (n=99), and a placebo arm (n=101); 57 sites across ten countries including the UK.
- Source
- 1 Lau et al., 2021
Limitation: Sponsor-funded (Novo Nordisk).
Limitations in full
Sponsor-funded (Novo Nordisk). Weight loss ranged from 6.0% to 10.8% across cagrilintide doses, against 3.0% on placebo.